Guangzhou Yuantai Pharmaceutical Technology

Guangzhou Yuantai Biological Pharmaceutical (also known as Guangzhou Yuantai Pharmaceutical Technology) is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative cell therapies and specialized pharmaceuticals. The company is primarily recognized for its advanced Chimeric Antigen Receptor T-cell (CAR-T) pipeline, which includes candidates targeting CD19, CD22, and BCMA for hematological malignancies. Its lead program, YTA-C19, is currently in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. In addition to its immunotherapy division, the company maintains a commercial portfolio of ophthalmic products, including approved generic eye drops for glaucoma and ocular hypertension. Yuantai operates a dedicated R&D and manufacturing facility in the Guangzhou Science City, leveraging proprietary platforms for cell engineering and complex drug formulation.